No Data
No Data
TD Cowen Maintains Xilio Therapeutics(XLO.US) With Buy Rating
Xilio Therapeutics GAAP EPS of -$0.24, Revenue of $2.4M
Xilio Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
Express News | Xilio Therapeutics Q2 Operating Expenses USD 17.061 Million
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
No Data